Baudax Bio, Inc. (BXRX) Stock Analysis
DELISTED 2023
What happened to Baudax Bio, Inc. (BXRX) stock?
Baudax Bio, Inc. (BXRX) no longer trades on public markets. It was delisted in November 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Baudax Bio, Inc. (BXRX) trades at $0.0218. Baudax Bio, Inc. is a pharmaceutical company focused on developing and commercializing products for acute care settings. Their lead product, ANJESO, targets moderate to severe pain management. Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for BXRX: BXRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BXRX against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
BXRX: the 2 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Baudax Bio, Inc. (BXRX) Healthcare & Pipeline Overview
Baudax Bio, Inc. is a pharmaceutical company specializing in acute care products, including ANJESO for pain management. With a pipeline focused on neuromuscular blocking agents and reversal agents, Baudax Bio operates in the competitive biotechnology sector, targeting unmet needs in hospital settings and aiming to improve patient outcomes.
What Is the Investment Thesis for BXRX?
Baudax Bio presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on acute care products, particularly ANJESO for pain management, addresses a significant market need. However, the company's negative profit margin of -4633.2% and gross margin of -452.3% highlight significant financial challenges. The successful development and commercialization of its pipeline products, including BX1000 and BX2000, are critical for future growth. Upcoming clinical trial results for BX1000 will be a key catalyst to watch. Investors should carefully consider the company's financial position and the inherent risks associated with pharmaceutical development.
Based on FMP financials and quantitative analysis
BXRX Key Highlights
ANJESO (meloxicam) injection is the company's only commercialized product, targeting moderate to severe pain management in acute care settings.
- The company's pipeline includes BX1000 (Phase II), BX2000 (Phase I), BX3000, and Dex-IN, all focused on neuromuscular blockade and sedation.
- Baudax Bio operates with a small team of 9 employees, indicating a lean operational structure.
- The company's negative profit margin of -4633.2% reflects significant challenges in achieving profitability.
- The company's stock has a beta of 1.58, indicating higher volatility compared to the overall market.
Who Are BXRX's Competitors?
BXRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BXRX's Key Strengths?
ANJESO provides a non-opioid alternative for pain management.
- Pipeline of NMBAs addresses a significant market need.
- Focus on acute care settings allows for targeted commercialization.
- Proprietary intranasal formulation of dexmedetomidine offers potential advantages.
What Are BXRX's Weaknesses?
Limited commercial product portfolio with reliance on ANJESO.
- Negative profit and gross margins indicate financial challenges.
- Small team size may limit operational capacity.
- Dependence on successful clinical trial outcomes for pipeline products.
What Could Drive BXRX Stock Higher?
BXRX catalyst: Results from Phase II clinical trials for BX1000, an intermediate-acting neuromuscular blocking agent, expected in late 2026.
- Continued commercialization efforts for ANJESO to increase market penetration and sales.
- Development progress of BX2000, an ultra-short acting NMBA, through Phase I clinical trials.
- Potential partnerships or licensing agreements to expand the product portfolio.
What Are the Key Risks for BXRX?
Financial-distress signal — its Altman Z-Score of -15.90 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for pipeline products, leading to delays or abandonment of development programs.
- Competition from established pharmaceutical companies with greater resources.
- Regulatory hurdles and delays in obtaining marketing approvals.
- Pricing pressures and reimbursement challenges for ANJESO and future products.
- Dependence on a limited number of key personnel.
What Are the Growth Opportunities for BXRX?
- Expansion of ANJESO's Market Share: ANJESO, as a non-opioid alternative for pain management, has the potential to capture a larger share of the acute pain market. The increasing awareness of the risks associated with opioid use creates a favorable environment for ANJESO's adoption. The company can focus on targeted marketing campaigns and partnerships with hospitals and healthcare providers to drive sales growth. The acute pain market is estimated to be worth billions of dollars, offering a significant opportunity for Baudax Bio.
- Advancement of BX1000 through Clinical Trials: The successful completion of Phase II clinical trials for BX1000, an intermediate-acting neuromuscular blocking agent, is a critical growth driver. Positive trial results would validate the drug's efficacy and safety, paving the way for Phase III trials and eventual commercialization. The market for neuromuscular blocking agents is substantial, driven by the increasing number of surgical procedures performed globally. The timeline for potential commercialization is estimated to be several years, contingent on successful trial outcomes and regulatory approvals.
- Development and Commercialization of BX2000: BX2000, an ultra-short acting NMBA, represents another significant growth opportunity. The drug's unique properties could make it a preferred option for certain surgical procedures requiring rapid onset and offset of neuromuscular blockade. The company needs to successfully complete Phase I trials and advance the drug through the clinical development process. The market for ultra-short acting NMBAs is a niche segment with potential for high margins. The timeline for commercialization is uncertain, given the early stage of development.
- Strategic Partnerships and Licensing Agreements: Baudax Bio can pursue strategic partnerships and licensing agreements to expand its product portfolio and geographic reach. Collaborating with larger pharmaceutical companies or specialized biotechnology firms can provide access to additional resources and expertise. Licensing agreements can generate revenue through upfront payments, milestones, and royalties. The market for pharmaceutical licensing is highly competitive, requiring a proactive and targeted approach.
- Expansion into New Therapeutic Areas: While currently focused on pain management and neuromuscular blockade, Baudax Bio can explore opportunities to expand into new therapeutic areas within the acute care setting. This could involve developing or acquiring products for other indications, such as infection control or critical care. Diversifying the product portfolio can reduce the company's reliance on a single product and mitigate risks associated with clinical trial failures or market competition. The timeline for expansion into new therapeutic areas is dependent on the company's financial resources and strategic priorities.
What Are BXRX's Competitive Advantages?
- Proprietary formulations of existing drugs.
- Pipeline of novel neuromuscular blocking agents.
- Intellectual property protection through patents.
- Established relationships with hospitals and healthcare providers.
What Does BXRX Do?
Baudax Bio, Inc., incorporated in 2019 and based in Malvern, Pennsylvania, is a pharmaceutical company dedicated to developing and commercializing innovative products for hospital and other acute care settings. The company's primary focus is on addressing unmet needs in pain management and neuromuscular blockade. Its lead product, ANJESO (meloxicam) injection, is designed for the management of moderate to severe pain, either alone or in combination with other non-NSAID analgesics. ANJESO provides a non-opioid alternative for pain relief, which is particularly relevant in the context of the ongoing opioid crisis. In addition to ANJESO, Baudax Bio has a pipeline of products under development, including BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) currently in Phase II clinical trials; BX2000, an ultra-short acting NMBA in Phase I clinical trials; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. These products aim to improve the management of patients undergoing surgical procedures or requiring sedation in acute care environments. Baudax Bio's strategy involves a combination of internal development and potential partnerships to advance its pipeline and expand its commercial reach. The company operates with a small team of 9 employees, reflecting a lean and focused approach to drug development and commercialization.
What Products and Services Does BXRX Offer?
- Develop and commercialize pharmaceutical products.
- Focus on hospital and acute care settings.
- Offer ANJESO (meloxicam) injection for pain management.
- Develop neuromuscular blocking agents (NMBAs).
- Develop NMBA reversal agents.
- Create proprietary intranasal formulations of dexmedetomidine.
How Does BXRX Make Money?
- Develop and commercialize proprietary pharmaceutical products.
- Generate revenue through sales of ANJESO.
- Out-license or partner for development and commercialization of pipeline products.
What Industry Does BXRX Operate In?
Baudax Bio operates within the biotechnology industry, which is characterized by high levels of innovation, regulation, and competition. The market for pain management and neuromuscular blocking agents is substantial, driven by the aging population, increasing surgical procedures, and the need for non-opioid pain relief options. Key trends include the development of novel drug delivery systems and personalized medicine approaches. Baudax Bio competes with larger pharmaceutical companies and specialized biotechnology firms, requiring a focused strategy and efficient execution to succeed.
Who Are BXRX's Key Customers?
- Hospitals
- Acute care facilities
- Anesthesiologists
- Pain management specialists
Company Profile
Baudax Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Malvern, US. The company is led by CEO Geraldine A. Henwood. BXRX has traded publicly since 2019.
Financial Health
Baudax Bio, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.90 places it in the distress zone, a signal of elevated financial risk.
BXRX Financials
Bull Case vs Bear Case
Bull Case
- ANJESO provides a non-opioid alternative for pain management.
- Pipeline of NMBAs addresses a significant market need.
- Focus on acute care settings allows for targeted commercialization.
- Proprietary intranasal formulation of dexmedetomidine offers potential advantages.
Bear Case
- Limited commercial product portfolio with reliance on ANJESO.
- Negative profit and gross margins indicate financial challenges.
- Small team size may limit operational capacity.
- Dependence on successful clinical trial outcomes for pipeline products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
BXRX Latest News
No recent news available for BXRX.
Leadership: Geraldine A. Henwood
CEO
Geraldine A. Henwood serves as the Chief Executive Officer of Baudax Bio, Inc. Her background includes extensive experience in the pharmaceutical industry, with a focus on commercialization and strategic development. She has held leadership positions at various pharmaceutical companies, where she was responsible for driving revenue growth and market share. Her expertise spans across multiple therapeutic areas, including pain management and anesthesia. She is known for her strategic vision and ability to build high-performing teams.
Track Record: Since assuming the role of CEO at Baudax Bio, Geraldine A. Henwood has focused on advancing the company's pipeline and expanding the commercial reach of ANJESO. Key achievements include the progression of BX1000 into Phase II clinical trials and the implementation of targeted marketing strategies for ANJESO. She has also focused on securing partnerships and collaborations to support the company's growth initiatives. Her leadership is focused on driving long-term value for shareholders.
Common Questions About BXRX (Healthcare)
What happened to Baudax Bio, Inc. (BXRX) stock?
Baudax Bio, Inc. (BXRX) no longer trades on public markets. It was delisted in November 2023. The figures below are historical and are not a current quote.
Can I still buy BXRX shares?
No. BXRX stopped trading on public markets in November 2023, so the shares are not available through a broker. Anything you see quoted for BXRX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before BXRX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Baudax Bio, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Baudax Bio, Inc. do?
Baudax Bio, Inc. is a pharmaceutical company focused on developing and commercializing products for hospital and other acute care settings. Their lead product, ANJESO (meloxicam) injection, is used for the management of moderate to severe pain, either alone or in combination with non-NSAID analgesics.
What do analysts say about BXRX stock?
Analyst coverage for Baudax Bio is limited, reflecting its small market capitalization and early stage of development. Key valuation metrics are difficult to assess due to the company's negative profitability. Growth considerations center on the successful development and commercialization of its pipeline products, particularly BX1000 and BX2000.
What are the main risks for BXRX?
Baudax Bio faces significant risks inherent in the biotechnology industry. Clinical trial failures for its pipeline products represent a major risk, as positive results are crucial for future growth. Competition from larger pharmaceutical companies with greater resources poses a threat to market share. Regulatory hurdles and delays in obtaining marketing approvals can impact timelines and increase costs.
How does Baudax Bio, Inc. manage patent expiration risks?
As a biotechnology company, Baudax Bio faces the ongoing challenge of managing patent expiration risks for its products. The company mitigates this risk by actively pursuing new patent applications for novel formulations, delivery methods, and therapeutic uses of its existing and pipeline products. This strategy aims to extend the period of market exclusivity and protect its intellectual property.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for BXRX may impact the accuracy of market sentiment analysis.
- Financial data is based on the most recent available information and may not reflect current performance.
- Clinical trial outcomes are inherently uncertain and can significantly impact the company's prospects.